ACRV

Acrivon Therapeutics Inc

Add to Watchlist

Advanced Chart

1.880

-0.03(-1.571%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.000

Open

1.930

VWAP

1.95

Vol

365.33K

Mkt Cap

59.14M

Low

1.860

Amount

712.87K

EV/EBITDA(TTM)

Total Shares

30.88M

-77.53M

EV/OCF(TTM)

P/S(TTM)

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.667

+30.72%

-0.570

+5.56%

-0.580

-1.69%

Estimates Revision

The market is revising No Change the revenue expectations for Acrivon Therapeutics, Inc. (ACRV) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 43.51%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+43.51%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 11.75 USD with a low forecast of 7.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.880

Low

7.00

Averages

11.75

High

19.00

Current: 1.880

Low

7.00

Averages

11.75

High

19.00

Oppenheimer

Outperform

downgrade

$9 -> $8

2025-08-14

Reason

Oppenheimer

Price Target

$9 -> $8

2025-08-14

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is on track for the second half of 2025.

JonesResearch

Buy

Hold

downgrade

2025-05-16

Reason

JonesResearch

Price Target

2025-05-16

downgrade

Buy

Hold

Reason

JonesResearch downgraded Acrivon Therapeutics to Hold from Buy without a price target. Investors may now be focused on ACR-2316 as a way to re-validate the company's tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some "real de-risking clinical data to comfortably" value Acrivon's biomarker-based selection platform.

Oppenheimer

Outperform

downgrade

$10 -> $9

2025-05-14

Reason

Oppenheimer

Price Target

$10 -> $9

2025-05-14

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$19

2025-03-28

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$19

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$22 → $19

2025-03-26

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$22 → $19

2025-03-26

Maintains

Strong Buy

Reason

Citizens Capital Markets

Silvan Tuerkcan

Buy

Reiterates

$17

2025-03-26

Reason

Citizens Capital Markets

Silvan Tuerkcan

Price Target

$17

2025-03-26

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Acrivon Therapeutics Inc (ACRV.O) is -0.76, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess Acrivon Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.79

Current PE

-0.76

Overvalued PE

-1.09

Undervalued PE

-4.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

66.90

Current PS

0.00

Overvalued PS

222.54

Undervalued PS

-88.74